Atlas Trials

Chromophobe Renal Cell Carcinoma

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Chromophobe Renal Cell Carcinoma

RecordFirmDate
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC (NCT04413123)Bradley A. McGregor, MD2020-11-05
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (NCT04071223)National Cancer Institute (NCI)2020-07-29
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy (NCT04623502)University of Texas Southwestern Medical Center2019-09-30
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (NCT03685448)Australian and New Zealand Urogenital and Prostate Cancer Trials Group2019-04-11
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma (NCT03635892)Memorial Sloan Kettering Cancer Center2018-08-13
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study (NCT06339138)Mayo Clinic2018-06-27
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma (NCT03541902)M.D. Anderson Cancer Center2018-05-15
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (NCT03177239)Australian and New Zealand Urogenital and Prostate Cancer Trials Group2017-10-19
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer (NCT01767636)Mayo Clinic2013-05-16
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer (NCT00126503)National Cancer Institute (NCI)2005-05-01

Track Chromophobe Renal Cell Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.